DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
June 15, 2017
Missouri Coalition for Community Behavioral Healthcare,
CEO Room/Lower Level, 221 Metro Dr., Jefferson City, MO

Committee Members Present
Patrick Bryant, Pharm D
Jennifer Kemp-Oestreich, Pharm D
Laura Kingsley, Pharm D
Morgan Sperry, Pharm D - * Non-voting member this meeting
Laine Young-Walker, M.D.

Guest of Committee Member
Rebecca Currie, UMKC School of Pharmacy

Contractors in Attendance:
Janelle Sheen, Pharm D, Conduent
Joshua Moore, Pharm D, Conduent
Luke Boehmer, Pharm D, Conduent
Rick Pope, Pharm D, Magellan

MO HealthNet Staff Present:
Stephen Calloway, R.Ph, Director of Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Jenna McTeer, RN, Clinical Management
Angela Wilson, Manager, Band I
Frances (Franki) Moseley, Administrative Office Support Assistant
Mitch Ruth, Fiscal Unit Manager
Dr. Timothy Kling, MD, Assistant Medical Director
Lisa E. Smith, Medicaid Specialist

Others Attending:

Mike Lafond, Abbvie
Ashley Polce, Abbvie
Christina Branmoger, Amgen
John Bullard, Amgen
Greg Kitchens, Artia Solutions
Jodi Jensen, Biogen
Melissa Laurie, Bristol-Myer Squibb
Gia McLean, Celgene
Jacqueline Glascock, Cure SMA
Donna Osterlund, Genzyme
Justin Crum, Gilead
Brian Strickland, Giliad
Teresa Blair, Ipsen
Jennifer Stoffel, Janssen
Susan Zalenski, Johnson & Johnson
Steve Naert, Lilly
Berend Koops, Merck
Misty Snodgrass, MO CCBH
Becky Ruth, MO State Representative, District 114
Don Kempir, Novo Nordisk
Jason Lurk, Novo Nordisk
Marla Wiedermann, Novo Nordisk
Matt Bradley, Novartis
Lon Lowery, Novartis
Tom Peddicord, Novartis
Anne McNamara, Otonomy
Rick Kegler, Otsuka
Jim Bauman, Pfizer

Others Attending:

Phillip King, Pfizer
John Kirby, Sanofi
Pratik Parikh, Sarema
Patrick Mosi, Sarepta
Chris Stanfield, Spernus
Randi Lewandowski, Teva
Maggie Murphy, Teva
Jim Osburn, Thera Tech
Matt Sheffield, Thera Tech
Aimee Redhair, UCB
Hayley Young, UCB
Chelsea Pendleton, Wipro
Geri Roling, Wipro

Welcome, Introductions and Opening Remarks	In the absence of Dr. Conrad Balcer, Chair, Dr. Laine Young-Walker, MD, called the meeting to order. Jennifer Kemp-Oestreich, Pharm D, introduced a student she had brought with her, Rebecca Currie from UMKC School of Pharmacy. Stephen Calloway introduced himself and started the introductions and opening remarks.
Minutes Approval	Minutes of the March 16, 2017 Drug PA meeting were reviewed and approved. Laura Kingsley motioned and Pat Bryant seconded the motion. (See Roll Call Vote)
Pharmacy Program/Budget Update	Stephen Calloway presented a brief power point. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking.
DUR Report	Stephen Calloway stated all PDL Renewals from the March 2017 Drug PA Meeting were ratified at the April 2017 DUR Board Meeting.
Old Business	
Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included March/April, 2017 PDL decisions to be implemented July 2017. Pending ratification, PDL decisions from the June 2017 Drug PA Committee meeting will be implemented October 2017. Schedules may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf

New Business	
New Drug Review	Stephen Calloway reviewed the new drug products that were identified for the quarter January, February March 2017 and the recommended status within the clinical program. • **Discussion –** A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending. • **Public Hearing –** Greg Kitchens, Artia Solutions, Emflaza and Phillip King, Pfizer, Eucrisa, provided testimony. • **Decision –** Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)
Clinical Edits	
Exondys 51	• **Discussion –** Mr. Calloway reviewed the criteria document and acknowledged assistance from MO Pediatric Neurology Specialists in creating the edit. • **Public Hearing –** Pratik Parikh, Sarema Therapeutics, provided testimony. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Spinraza	• **Discussion –** Mr. Calloway reviewed the criteria document and acknowledged assistance from MO Pediatric Neurology Specialists in creating the edit. • **Public Hearing –** Becky Ruth, MO State Representative District 114, Jackie Glascock, Scientific Program, and Jodi Jensen, Biogen, Inc., all provided testimony. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Short-Acting (Single-agent) Opioids	• **Discussion –** Mr. Calloway reviewed the criteria document. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Preferred Drug List (PDL)	
Amylin Analogs	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antihyperuricemic Agents	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No Comments Entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Bile Salt Agents	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No comments entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Bone Deossification Suppression Agents	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No comments entered. • **Decision –** The Committee voted to accept this PDL edit as presented, with further review into the criteria. (See Roll Call Vote)
BPH Agents (formerly Androgen Hormone Inhibitors)	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No comments entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Cephalosporin Antibiotics-Oral (New)	• **Discussion –** This is a new PDL class being recommended for implementation. • **Public Hearing –** No comments entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Agents for Cryopyrin-Associated Periodic Syndrome (CAPS)	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** No comments entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
DPP-IV Inhibitors	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** No comments entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Electrolyte Depleters	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
FluoroQuinolones	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** No comments entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Gastrointestinal (GI) Antibiotics-Oral (New)	• **Discussion –** This is a new PDL class being recommended for implementation. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
GLP-1 Receptor Agonists	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Growth Hormones and Growth Factors	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** Jim Osburn, Thera Tech, provided testimony on Egrifta. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Hematopoietic Agents	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Insulins	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Insulins-Long Acting	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** Jason Lurk, Novo Nordisk, provided testimony onTresiba. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Insulins-Mix	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Insulins-Rapid Acting	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Intravaginal Antibiotics	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Macrolides-Adult	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Macrolides-Pediatric	• **Discussion –** Mr. Calloway stated there was one change recommended for this class. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Methotrexate-Oral and Injectible (New)	• **Discussion –** This is a new PDL class being recommended for implementation. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Multiple Sclerosis Agents	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** Jodi Jensen, Biogen Inc., provided testimony on Tecfidera and Maggie Murphy, Teva, provided testimony on Copaxone. Donna Osterlund, Genzyme, spoke about the criteria. The Committee also reviewed a letter from the Multiple Sclerosis Society. • **Decision –**The Committee voted to accept this PDL edit with one revision to the approval criteria. (See Roll Call Vote)

Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Oral AntiDiabetics: Biguanides	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
AntiDiabetic Combinations: Oral and Injectible	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** Jason Lurk, Novo Nordisk, provided testimony on Xultophy. • **Decision –** The Committee voted to accept this PDL edit as presented, but will conduct further review on criteria for the Insulin/GLP-1 Combinations. (See Roll Call Vote)
Oral AntiDiabetics: Meglitinides	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Oral AntiDiabetics: 2nd Generation Sulfonylureas	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Oral AntiDiabetics: Thiazolidinediones	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Penicillins (New)	• **Discussion –** This is a new PDL class being recommended for implementation. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. Dr. Kemp Oestreich recommended that MHD staff provide a blast or otherwise notify providers about the new antibiotic PDL's. (See Roll Call Vote)
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** Jason Lurk, Novo Nordisk, provided testimony on Invokana. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Targeted Immune Modulators (formerly Biologics-DMARDs)	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** Haylee Young, UCB, presented testimony on Cimzia. Gia McClean, Celgene, presented testimony on Otezla. Lon Lowry, Novartis, presented testimony on Cosentyx. Melissa Laurie, Bristol-Myer Squibb presented testimony on Orencia. Phillip King, Pfizer, presented testimony on Xeljanz XR. • **Decision –** The Committee voted to accept this PDL edit as presented with a proposal and amendment, pending clarification with Magellan PDL vendor. (See Roll Call Vote)

Tetracyclines	• **Discussion –** Mr. Calloway stated there are no changes recommended for this class. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Urinary Tract Antispasmodics	• **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • **Public Hearing –** No comments were entered. • **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Preferred Drug List Announcement	A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf

Conduent Update	Luke Boehmer, Pharm D, reviewed presented SVR compliance data for Hepatitis C patients dating back to 2013. To be compliant, patients on a 12 week regimen had to have at least one SVR in 30 weeks after starting treatment. For a 24 week regimen, patients needed to have 2 SVRs done within 60 weeks of starting treatment. Data showed a 93% compliance rate on 12 week regimens and a 97% compliance rate on 24 week regimens. Mr. Boehmer presented the need to look for more SVR data to ensure compliance. For a 12 week regimen, patients should have on SVR done at 4 weeks after starting treatment, 10-12 weeks after, and approximately 24 weeks after. For a 24 week regimen, patients should have an SVR done at 4 weeks after, 10-12 weeks after, 24 weeks after, and around 36 weeks after. (This is not counting the initial SVR before patient starts treatment). Mr. Boehmer presented normal Spend PMPM, Claims PMPM, and Cost per Claim for the Hepatitis C agents. Mr. Boehmer presented the Inpatient and ER utilization for patients that were compliant with getting Labs Drawn vs. those that weren't compliant. Mr. Boehmer reviewed the Hepatitis C Regimens and those regimens that resulted in another regimen. Mr. Boehmer discussed the POS and Call Center Statistics for the changes made to the Opioid data and the dosage and units impacted based on the changes that we had made so far to the Opioid edit Lastly, Mr. Boehmer discussed the expected impact of lowering all drugs to the 120 morphine equivalent maximum dose.
Program Utilization: Top 25 Drugs Summary	Luke Boehmer, Pharm D, reviewed the Top 25 Drugs Summary Reports for the1st, 2nd, 3rd, & 4th quarter 2017. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
Call Center Statistics/ CyberAccess Reports	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Luke Boehmer reviewed how many sites/physical locations are trained and have access to CyberAccess. Reports also detailed the number and type of prescribers and active users on CyberAccess.

Adjourn	The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. (See attached roll call) Attendees were advised to check the calendar of events on the MHD website for meeting location changes over the next few months. The next meeting of the Drug Prior Authorization Committee is scheduled for Thursday, **September 21, 2017** at the **Department of Natural Resources, Lacharette/Nightingale Rooms, 1101 Riverside Dr., Jefferson City, MO.**

Roll Call Votes June 15, 2107

Member	**Minutes**	**New Drug Review**	**Exondys 51**	**Spinraza**	**Short Acting (Single-Agent) Opioid Clinical Edit**	**Amylin Analogs**	**Antihyperuricemic Agents**
Conrad Balcer, D.O.	-	-	-	-	-	-	-
Pat Bryant, Pharm D	M	Y	Y	Y	S	Y	Y
Laine Young-Walker, M.D.	S	M	S	M	M	Y	M
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	Y	Y	M	Y	Y	M	Y
Laura Kingsley, Pharm D	Y	S	Y	S	Y	S	S

Member	Bile Salts Agents	Bone Deossification Suppression Agents (calcitonin)	BPH Agents (formerly Androgen Hormone Inhibitors)	Cephalosporins and Related Antibiotics-Oral	Cryopyrin-associated Periodic Syndrome(CAPS) Agents	DPP-IV (Dipepeidyl Peptidase-4) Inhibitors	Electrolyte Depleters (Phosphate Binders)
Conrad Balcer, D.O.	-	-	-	-	-	-	-
Pat Bryant, Pharm D	M	SY	M	Y	Y	Y	Y
Laine Young-Walker, M.D.	Y		Y	Y	S	Y	M
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestreich, Pharm D	S	Y	Y	M	M	M	S
Laura Kingsley, Pharm D	Y	M	S	S	Y	S	Y

Member	Fluoroquinolones-Oral	GI Antibiotics-Oral	GLP-1 Receptor Agonists(Anti-Diabetic Mimetics)	Growth Hormones and Growth Factors	Hematopoietic Agents	Insulins	Insulins-Long Acting
Conrad Balcer, D.O.	-	-	-	-	-	-	-
Pat Bryant, Pharm D	Y	Y	M	Y	Y	Y	Y
Laine Young-Walker, M.D.	Y	Y	Y	S	S	M	Y
Morgan Sperry, Pharm D	-	-	-	-	-	-	-
Jennifer Kemp-Oestreich, Pharm D	M	S	S	M	M	Y	M
Laura Kingsley, Pharm D	S	M	Y	Y	Y	S	S

Member	Insulins-Mix	Insulins-Rapid Acting	Intravaginal Antibiotics	Macrolides-Adult	Macrolides-Pediatric	Methotrexate Products-Oral and Injectable	Multiple Sclerosis(MS) Agents
Conrad Balcer, D.O.	-	-	-	-	-	-	-
Pat Bryant, Pharm D	M	Y	Y	Y	S	Y	M
Laine Young-Walker, M.D.	Y	S	S	Y	Y	Y	Y
Morgan Sperry, Pharm D	-	-	-	-	-	-	-
Jennifer Kemp-Oestreich, Pharm D	Y	Y	M	M	Y	S	Y
Laura Kingsley, Pharm D	S	M	Y	S	M	M	S

Member	Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors	Oral Anti-Diabetics: Biguanides	Oral Anti-Diabetics: Combinations	Oral Anti-Diabetics: Meglitinides	Oral Anti-Diabetics: Sulfonylureas 2nd Generation	Oral Anti-Diabetics: Thiazolidinediones	Penicillins
Conrad Balcer, D.O.	-	-	-	-	-	-	-
Pat Bryant, Pharm D	S	Y	Y	S	S	S	Y
Laine Young-Walker, M.D.	Y	Y	Y	Y	Y	Y	Y
Morgan Sperry, Pharm D	-	-	-	-	-	-	-
Jennifer Kemp-Oestreich, Pharm D	Y	S	M	Y	M	M	M
Laura Kingsley, Pharm D	M	M	S	M	Y	Y	S

Member	Sodium-Glucose Co-Tranporter 2 GLT2) Inhibitors	Targeted Immune Modulators	Tetracyclines	Urinary Tract Antispasmodics	Meeting Adjourned Pursuant to Section 610.021 (14)-(5)		
Conrad Balcer, D.O.	-	-	-	-	-	-	-
Pat Bryant, Pharm D	M	Y	M	M	Y		
Laine Young-Walker, M.D.	Y	Y	Y	Y	Y		
Morgan Sperry, Pharm D	-	-	-	-	-	-	-
Jennifer Kemp-Oestreich, Pharm D	Y	M	Y	Y	M		
Laura Kingsley, Pharm D	S	S	S	S	S		